1. Home
  2. SHIP vs IFRX Comparison

SHIP vs IFRX Comparison

Compare SHIP & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Seanergy Maritime Holdings Corp.

SHIP

Seanergy Maritime Holdings Corp.

HOLD

Current Price

$16.92

Market Cap

335.9M

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$1.86

Market Cap

303.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SHIP
IFRX
Founded
2008
2007
Country
Greece
Germany
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
335.9M
303.4M
IPO Year
2008
2017

Fundamental Metrics

Financial Performance
Metric
SHIP
IFRX
Price
$16.92
$1.86
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$17.00
$6.25
AVG Volume (30 Days)
276.1K
873.9K
Earning Date
05-26-2026
05-07-2026
Dividend Yield
2.93%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$20.07
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$13.34
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.21
$0.78
52 Week High
$18.48
$2.95

Technical Indicators

Market Signals
Indicator
SHIP
IFRX
Relative Strength Index (RSI) 60.19 40.66
Support Level $13.60 $1.58
Resistance Level N/A $1.94
Average True Range (ATR) 0.79 0.12
MACD 0.16 0.00
Stochastic Oscillator 72.20 21.35

Price Performance

Historical Comparison
SHIP
IFRX

About SHIP Seanergy Maritime Holdings Corp.

Seanergy Maritime Holdings Corp is an international shipping company that provides marine dry bulk transportation services through a modern fleet of Capesize vessels. It generates a majority of its revenue from the vessels. The company's fleet of vessels includes Blueship, Meiship, Kaizenship, Iconship, Titanship, Flagship, Paroship, Worldship, Hellasship, Partnership, Championship, Patriotship, Dukeship, Honorship, Fellowship, Knightship, Lordship, Premiership, Squireship, and Friendship.

About IFRX InflaRx N.V.

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: